Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Assets (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Current Assets for 10 consecutive years, with $466.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 24.78% to $466.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $466.9 million through Dec 2025, up 24.78% year-over-year, with the annual reading at $466.9 million for FY2025, 24.78% up from the prior year.
  • Current Assets for Q4 2025 was $466.9 million at Rhythm Pharmaceuticals, down from $494.8 million in the prior quarter.
  • The five-year high for Current Assets was $494.8 million in Q3 2025, with the low at $235.8 million in Q1 2024.
  • Average Current Assets over 5 years is $344.6 million, with a median of $347.3 million recorded in 2022.
  • The sharpest move saw Current Assets skyrocketed 59.89% in 2021, then crashed 38.5% in 2022.
  • Over 5 years, Current Assets stood at $308.4 million in 2021, then increased by 14.87% to $354.2 million in 2022, then dropped by 12.98% to $308.3 million in 2023, then rose by 21.39% to $374.2 million in 2024, then grew by 24.78% to $466.9 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $466.9 million, $494.8 million, and $360.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.